.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Daiichi Sankyo
Fish and Richardson
QuintilesIMS
Deloitte
Argus Health
Cipla
Federal Trade Commission
Cantor Fitzgerald
Moodys

Generated: September 19, 2017

DrugPatentWatch Database Preview

VIVITROL Drug Profile

« Back to Dashboard

What is the patent landscape for Vivitrol, and when can generic versions of Vivitrol launch?

Vivitrol is a drug marketed by Alkermes and is included in one NDA. There are nineteen patents protecting this drug.

This drug has one hundred and fifty-six patent family members in thirty-three countries.

The generic ingredient in VIVITROL is naltrexone. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the naltrexone profile page.

Summary for Tradename: VIVITROL

Patents:19
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list25
Clinical Trials: see list57
Patent Applications: see list5,829
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VIVITROL at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006RXYesYes► Subscribe► Subscribe ► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VIVITROL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006► Subscribe► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006► Subscribe► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006► Subscribe► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VIVITROL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,110,503 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent► Subscribe
6,540,393 Apparatus for preparing microparticles using in-line solvent extraction► Subscribe
7,300,671Method and apparatus for preparing microparticles using in-line solvent extraction► Subscribe
7,371,406Preparation of injectable suspensions having improved injectability► Subscribe
7,510,730Apparatus and method for preparing microparticles using in-line solvent extraction► Subscribe
6,290,983 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent► Subscribe
6,861,016 Apparatus and method for preparing microparticles► Subscribe
6,705,757 Method and apparatus for preparing microparticles using in-line solvent extraction► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VIVITROL

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)0191720► Subscribe
Australia2750801► Subscribe
Japan2003534366► Subscribe
Denmark1140029► Subscribe
Australia2005239989► Subscribe
Israel126509► Subscribe
Canada2352818► Subscribe
Argentina046034► Subscribe
Denmark0904063► Subscribe
European Patent Office1754469► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Chinese Patent Office
Farmers Insurance
Cerilliant
Julphar
Express Scripts
US Army
Novartis
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot